Literature DB >> 7561701

52-kD SS-A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipper-minus autoantigen expressed in fetal and adult heart.

E K Chan1, F Di Donato, J C Hamel, C E Tseng, J P Buyon.   

Abstract

The 52-kD SS-A/Ro protein is one of the antigenic targets strongly associated with the autoimmune response in mothers whose children have manifestations of neonatal lupus. In addition to the cDNA clone we previously reported for the full-length 52-kD SS-A/Ro protein, an interesting MOLT-4 cDNA clone, p52-2, was found to have an internal deletion of 231 nucleotides including the domain encoding the leucine zipper motif. To further investigate the nature of this deletion, genomic DNA clones were isolated from a lambda FIXII library. The complete gene for the full-length 52-kD protein (alpha form, 52 alpha) spans 10 kb of DNA and is composed of seven exons. Exon 1 contains only the 5' untranslated sequence, while the translation initiation codon is located 3 kb downstream in exon 2, which also encodes the three zinc finger motifs. Exon 4 encodes amino acids 168-245, including the coiled coil/leucine zipper domain. Exon 7 is the longest and encodes the rfp-like domain and the 3' untranslated region. The cDNA p52-2 can now be accounted for as a product of alternative messenger RNA (mRNA) derived from the splicing of exon 3 to exon 5, skipping exon 4, which results in a smaller protein (52 beta) with a predicted molecular weight of 45,000. An initial approach to identifying this alternatively spliced form in the human heart used a ribonuclease protection assay. Using an RNA probe corresponding to bases 674-964 of the full-length cDNA, two protected mRNA fragments were identified, a 290-bp fragment corresponding to expression of 52 alpha and a smaller fragment of 144 bp, the predicted size of 52 beta. Using reverse transcription followed by polymerase chain reaction, cDNAs from a 16-wk fetal heart, 24-wk heart, and adult heart were amplified with primers flanking exon 4. Two polymerase chain reaction products were observed in each tissue, one 1.0 kb likely representing 52 alpha and a second 0.78 kb, consistent with 52 beta. The 0.78-kb fragment identified in the 16-wk heart was cloned, and DNA sequencing confirmed the 52 beta type. Immunoprecipitation of in vitro-translated 35S-labeled 52 beta form was performed to evaluate the antigenicity of this novel form of 52-kD SS-A/Ro. 26 (87%) of 30 sera tested from mothers whose children were known to have neonatal lupus immunoprecipitated the 52 beta form.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561701      PMCID: PMC2192297          DOI: 10.1084/jem.182.4.983

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

1.  The ret oncogene products are membrane-bound glycoproteins phosphorylated on tyrosine residues in vivo.

Authors:  M Taniguchi; T Iwamoto; M Hamaguchi; M Matsuyama; M Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1991-11-27       Impact factor: 3.575

Review 2.  An analysis of vertebrate mRNA sequences: intimations of translational control.

Authors:  M Kozak
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

3.  Determination of messenger RNA 5'-ends by reverse transcription of the cap structure.

Authors:  J Hirzmann; D Luo; J Hahnen; G Hobom
Journal:  Nucleic Acids Res       Date:  1993-07-25       Impact factor: 16.971

4.  Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies.

Authors:  J P Buyon; R J Winchester; S G Slade; F Arnett; J Copel; D Friedman; M D Lockshin
Journal:  Arthritis Rheum       Date:  1993-09

5.  Sera from patients with rheumatic diseases recognize different epitope regions on the 52-kD Ro/SS-A protein.

Authors:  B Bozic; G J Pruijn; B Rozman; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

6.  The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms.

Authors:  M B Frank; K Itoh; A Fujisaku; P Pontarotti; M G Mattei; B R Neas
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

7.  Maternal autoantibodies and congenital heart block: no evidence for the existence of a unique heart block-associated anti-Ro/SS-A autoantibody profile.

Authors:  J F Meilof; I M Frohn-Mulder; P A Stewart; A Szatmari; J Hess; C H Veldhoven; R J Smeenk; A J Swaak
Journal:  Lupus       Date:  1993-08       Impact factor: 2.911

8.  Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen.

Authors:  E K Chan; J C Hamel; J P Buyon; E M Tan
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

9.  Protein heterogeneity in the human Ro/SSA ribonucleoproteins. The 52- and 60-kD Ro/SSA autoantigens are encoded by separate genes.

Authors:  K Itoh; Y Itoh; M B Frank
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

10.  Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La.

Authors:  H Julkunen; P Kurki; R Kaaja; R Heikkilä; I Immonen; E K Chan; E Wallgren; C Friman
Journal:  Arthritis Rheum       Date:  1993-11
View more
  10 in total

Review 1.  Neonatal lupus.

Authors:  Antonio Brucato; Rolando Cimaz; Marco Stramba-Badiale
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

2.  Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein.

Authors:  Abdelmajid Sabile; Andrea Michael Meyer; Christiane Wirbelauer; Daniel Hess; Ulrike Kogel; Martin Scheffner; Wilhelm Krek
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

3.  A master autoantigen-ome links alternative splicing, female predilection, and COVID-19 to autoimmune diseases.

Authors:  Julia Y Wang; Michael W Roehrl; Victor B Roehrl; Michael H Roehrl
Journal:  J Transl Autoimmun       Date:  2022-02-25

4.  Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes.

Authors:  Bernard Ng; Fan Yang; David P Huston; Yan Yan; Yu Yang; Zeyu Xiong; Leif E Peterson; Hong Wang; Xiao-Feng Yang
Journal:  J Allergy Clin Immunol       Date:  2004-12       Impact factor: 10.793

Review 5.  Congenital heart block: evidence for a pathogenic role of maternal autoantibodies.

Authors:  Aurélie Ambrosi; Marie Wahren-Herlenius
Journal:  Arthritis Res Ther       Date:  2012-04-26       Impact factor: 5.156

6.  Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus.

Authors:  Ryusuke Yoshimi; Yoshiaki Ishigatsubo; Keiko Ozato
Journal:  Int J Rheumatol       Date:  2012-06-04

Review 7.  Genetic aspects of Sjögren's syndrome.

Authors:  Anne I Bolstad; Roland Jonsson
Journal:  Arthritis Res       Date:  2002-09-24

8.  Autoantibodies against the Immunoglobulin-Binding Region of Ro52 Link its Autoantigenicity with Pathogen Neutralization.

Authors:  Peter D Burbelo; Leyla Y Teos; Jesse L Herche; Michael J Iadarola; Ilias Alevizos
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.996

Review 9.  Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease.

Authors:  Pingping Ren; Luying Lu; Shasha Cai; Jianghua Chen; Weiqiang Lin; Fei Han
Journal:  Front Immunol       Date:  2021-08-17       Impact factor: 7.561

10.  A Master Autoantigen-ome Links Alternative Splicing, Female Predilection, and COVID-19 to Autoimmune Diseases.

Authors:  Julia Y Wang; Michael W Roehrl; Victor B Roehrl; Michael H Roehrl
Journal:  bioRxiv       Date:  2021-08-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.